Asia-Pacific Oncology Molecular Diagnostics Market by Application (Breast Cancer, Lung Cancer, Colorectal Cancer, Hematological Cancer & Others), End User (Hospitals, Reference Laboratories, & Others), Country (Australia, Vietnam, Thailand, Philippines & Rest of Asia-Pacific): Regional Opportunity Analysis and Industry Forecast, 2019–2026
- ALL3931818
- 158 Pages
- May 2020
- Medical Devices
Molecular diagnostics is a set of cumulative techniques used for analyzing biological markers at molecular level such as genome and proteome. It is used for diagnosis and prediction of various infectious diseases, cancers, and other genetic disorders. Advancements in molecular diagnostics, including increased precision, faster turnarounds, and reduced costs act as key drivers for better genetic information.
The market is segmented on the basis of application, end user, and country. By application, it is categorized into lung, colorectal, breast, hematological, and others. By end user, it is segmented into hospitals, reference laboratories, and others (research institutes and academics). The hospitals segment was the highest contributor to the market, with $184.27 million in 2018, and is estimated to reach $354.46 million by 2026, at a CAGR of 9.0% during the forecast period.
Country wise, the market is divided into Australia, Vietnam, the Philippines, Thailand, and rest of Asia-Pacific. The oncology molecular diagnostics market growth, by country, is attributed to higher adoption and acceptance of personalized medicine, upgradation of healthcare infrastructure, and higher investments for R&D. Further, the market growth is attributed to increase in number of patients suffering from cancer in Asia-Pacific.
The key players profiled in this report include F. Hoffmann-La Roche AG, BioMérieux SA, Abbott Laboratories, Qiagen N.V., Sysmex, Danaher Corporation, S.A., Danaher, and Siemens Healthcare GmbH.
KEY BENEFITS FOR STAKEHOLDERS
ü This report provides a detailed quantitative analysis of the current market trends and future estimations from 2019 to 2026, which assists to identify the prevailing market opportunities.
ü An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate region-specific plans.
ü A comprehensive analysis of the factors that drive and restrain the growth of the Asia-Pacific oncology molecular diagnostics market is provided.
ü An extensive analysis of various regions provides insights that allow companies to strategically plan their business moves.
KEY MARKET SEGMENTS
By Application
• Breast cancer
o By Technology
§ PCR
• By Type
o Instruments
o Reagents
o Software & Services
§ NGS
• By Type
o Instruments
o Reagents
o Software & Services
§ Flow Cytometry
• By Type
o Instruments
o Reagents
o Software & Services
§ FISH
• By Type
o Instruments
o Reagents
o Software & Services
§ CISH
• By Type
o Instruments
o Reagents
o Software & Services
o
§ Others
• By Type
o Instruments
o Reagents
o Software & Services
• Lung cancer
o By Technology
§ PCR
• By Type
o Instruments
o Reagents
o Software & Services
§ NGS
• By Type
o Instruments
o Reagents
o Software & Services
§ Flow Cytometry
• By Type
o Instruments
o Reagents
o Software & Services
§ FISH
• By Type
o Instruments
o Reagents
o Software & Services
§ CISH
• By Type
o Instruments
o Reagents
o Software & Services
§ Others
• By Type
o Instruments
o Reagents
o Software & Services
• Colorectal cancer
o By Technology
§ PCR
• By Type
o Instruments
o Reagents
o Software & Services
§ NGS
• By Type
o Instruments
o Reagents
o Software & Services
§ Flow Cytometry
• By Type
o Instruments
o Reagents
o Software & Services
§ FISH
• By Type
o Instruments
o Reagents
o Software & Services
§ CISH
• By Type
o Instruments
o Reagents
o Software & Services
§ Others
• By Type
o Instruments
o Reagents
o Software & Services
• Hematological cancer
o By Technology
§ PCR
• By Type
o Instruments
o Reagents
o Software & Services
§ NGS
• By Type
o Instruments
o Reagents
o Software & Services
§ Flow Cytometry
• By Type
o Instruments
o Reagents
o Software & Services
§ FISH
• By Type
o Instruments
o Reagents
o Software & Services
§ CISH
• By Type
o Instruments
o Reagents
o Software & Services
§ Others
• By Type
o Instruments
o Reagents
o Software & Services
• Others
o By Technology
§ PCR
• By Type
o Instruments
o Reagents
o Software & Services
§ NGS
• By Type
o Instruments
o Reagents
o Software & Services
§ Flow Cytometry
• By Type
o Instruments
o Reagents
o Software & Services
§ FISH
• By Type
o Instruments
o Reagents
o Software & Services
§ CISH
• By Type
o Instruments
o Reagents
o Software & Services
§ Others
• By Type
o Instruments
o Reagents
o Software & Services
• By End user
• Hospitals
• Reference Laboratories
• Others
• By Country
• Australia
• Thailand
• The Philippines
• Vietnam
• Rest of Asia-Pacific
KEY MARKET PLAYERS
• F. Hoffmann-La Roche AG
• BioMérieux SA
• Abbott Laboratories
• Qiagen N.V.
• Sysmex Corporation
• Danaher Corporation, S.A.
• Siemens Healthcare GmbH.
• DiaSorin
• Illumina
• Agilent Technologies
1.1.Report description
1.2.Key benefits
1.3.Key market segments
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools & models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Key findings
3.1.1.Top Investment Pockets
3.1.2.Top Player Positioning, 2018
3.1.3.Key forces shaping the Asia-Pacific oncology molecular diagnostics market
3.2.Market dynamics
3.2.1.Drivers
3.2.1.1.Rise in prevalence of various types of cancersW
3.2.1.2.Growth in funding by governmentsW
3.2.1.3.Growth in biomarker identification
3.2.2.Restraints
3.2.2.1.Lack of skilled professionals
3.2.2.2.Stringent regulatory requirements for product approvals
3.2.3.Opportunities
3.2.3.1.Advancements in genomics and proteomics
3.3.Regulatory guidelines for molecular diagnostics
3.4.Recommended guidelines for oncology molecular diagnostics tests
3.5.Insights on clinical flow cytometry panel
3.6.Pricing ranges for technology
CHAPTER 4:ASIA-PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION
4.1.Overview
4.1.1.Asia-Pacific oncology molecular diagnostics market, by application
4.2.Colorectal cancer
4.2.1.Asia-Pacific oncology molecular diagnostics market, by technology for colorectal cancer
4.2.2.Colorectal oncology molecular diagnostics market, by PCR-based technology
4.2.3.Colorectal oncology molecular diagnostics market, by NGS based technology
4.2.4.Colorectal oncology molecular diagnostics market, by flow cytometry based technology
4.2.5.Colorectal oncology molecular diagnostics market, by FISH based technology
4.2.6.Colorectal oncology molecular diagnostics market, by CISH based technology
4.2.7.Colorectal oncology molecular diagnostics market, by others based technology
4.3.Hematological cancer
4.3.1.Market size and forecast
4.3.2.Hematological oncology molecular diagnostics market, by PCR-based technology
4.3.3.Hematological oncology molecular diagnostics market, by NGS based technology
4.3.4.Hematological oncology molecular diagnostics market, by flow cytometry based technology
4.3.5.Hematological oncology molecular diagnostics market, by FISH based technology
4.3.6.Hematological oncology molecular diagnostics market, by CISH based technology
4.3.7.Hematological oncology molecular diagnostics market, by others based technology
4.4.Breast cancer
4.4.1.Market size and forecast
4.4.2.Breast oncology molecular diagnostics market, by PCR-based technology
4.4.3.Breast oncology molecular diagnostics market, by NGS based technology
4.4.4.Breast oncology molecular diagnostics market, by flow cytometry based technology
4.4.5.Breast oncology molecular diagnostics market, by FISH based technology
4.4.6.Breast oncology molecular diagnostics market, by CISH based technology
4.4.7.Breast oncology molecular diagnostics market, by others based technology
4.5.Lung cancer
4.5.1.Market size and forecast
4.5.2.Lung oncology molecular diagnostics market, by PCR-based technology
4.5.3.Lung oncology molecular diagnostics market, by NGS based technology
4.5.4.Lung oncology molecular diagnostics market, by flow cytometry based technology
4.5.5.Lung oncology molecular diagnostics market, by FISH based technology
4.5.6.Lung oncology molecular diagnostics market, by CISH based technology
4.5.7.Lung oncology molecular diagnostics market, by others based technology
4.6.Other cancers
4.6.1.Market size and forecast
4.6.2.Others oncology molecular diagnostics market, by PCR-based technology
4.6.3.Others oncology molecular diagnostics market, by NGS based technology
4.6.4.Others oncology molecular diagnostics market, by flow cytometry based technology
4.6.5.Others oncology molecular diagnostics market, by FISH based technology
4.6.6.Others oncology molecular diagnostics market, by CISH based technology
4.6.7.Others oncology molecular diagnostics market, by others based technology
CHAPTER 5:ASIA-PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY END USER
5.1.Overview
5.1.1.Market size and forecast
5.2.Hospitals
5.2.1.Market size and forecast
5.3.Reference laboratories
5.3.1.Market size and forecast
5.4.Others
5.4.1.Market size and forecast
CHAPTER 6:ASIA-PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY
6.1.Overview
6.1.1.Key market trends and opportunities
6.1.2.Asia-Pacific Oncology Molecular Diagnostics market, by country
6.2.Australia
6.2.1.Australia oncology molecular diagnostics market, by application
6.2.2.Australia oncology molecular diagnostics market, by end user
6.2.3.Market share analysis of top players, 2018
6.3.Vietnam
6.3.1.Vietnam oncology molecular diagnostics market, by application
6.3.2.Vietnam oncology molecular diagnostics market, by end user
6.3.3.Market share analysis of top players, 2018
6.4.Thailand
6.4.1.Thailand oncology molecular diagnostics market, by application
6.4.2.Thailand oncology molecular diagnostics market, by end user
6.4.3.Market share analysis of top players, 2018
6.5.Philippines
6.5.1.Philippines oncology molecular diagnostics market, by application
6.5.2.Philippines oncology molecular diagnostics market, by end user
6.5.3.Market share analysis of top players, 2018
6.6.Rest of Asia-Pacific
6.6.1.Rest of Asia-Pacific oncology molecular diagnostics market, by application
6.6.2.Rest of Asia-Pacific oncology molecular diagnostics market, by end user
CHAPTER 7:COMPANY PROFILES
7.1.ABBOTT LABORATORIES
7.1.1.Company overview
7.1.2.Company snapshot
7.1.3.Operating business segments
7.1.4.Product portfolio
7.1.5.Business performance
7.2.bioMérieux SA
7.2.1.Company overview
7.2.2.Company snapshot
7.2.3.Product portfolio
7.2.4.Business performance
7.2.5.Key strategic moves and developments
7.3.Qiagen N.V.
7.3.1.Company overview
7.3.2.Company snapshot
7.3.3.Operating business segments
7.3.4.Product portfolio
7.3.5.Business performance
7.3.6.Key strategic moves and developments
7.4.F. Hoffmann-La Roche Ltd
7.4.1.Company overview
7.4.2.Company snapshot
7.4.3.Operating business segments
7.4.4.Product portfolio
7.4.5.Business performance
7.4.6.Key strategic moves and developments
7.5.Siemens Healthineers
7.5.1.Company overview
7.5.2.Company snapshot
7.5.3.Operating business segments
7.5.4.Product portfolio
7.5.5.Business performance
7.6.Danaher (Cepheid)
7.6.1.Company overview
7.6.2.Company snapshot
7.6.3.Operating business segments
7.6.4.Product portfolio
7.6.5.Business performance
7.6.6.Key strategic moves and developments
7.7.Diasorin SPA
7.7.1.Company overview
7.7.2.Company snapshot
7.7.3.Product portfolio
7.7.4.Business performance
7.7.5.Key strategic moves and developments
7.8.Illumina Inc.
7.8.1.Company overview
7.8.2.Company snapshot
7.8.3.Operating business segments
7.8.4.Product portfolio
7.8.5.Business performance
7.8.6.Key strategic moves and developments
7.9.Agilent Technologies Inc.
7.9.1.Company overview
7.9.2.Company snapshot
7.9.3.Operating business segments
7.9.4.Product portfolio
7.9.5.Business performance
7.9.6.Key strategic moves and developments
7.10.Sysmex Corporation
7.10.1.Company overview
7.10.2.Company snapshot
7.10.3.Operating business segments
7.10.4.Product portfolio
7.10.5.Business performance
7.10.6.Key strategic moves and developments
TABLE 01.ASIA-PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 02.ASIA PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY FOR COLORECTAL CANCER, 2018–2026 ($MILLION)
TABLE 03.COLORECTAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY PCR-BASED TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 04.COLORECTAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY NGS BASED TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 05.COLORECTAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY FLOW CYTOMETRY BASED TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 06.COLORECTAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY FISH BASED TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 07.COLORECTAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY CISH BASED TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 08.COLORECTAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY OTHERS BASED TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 09.ASIA PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES , BY COUNTRY, 2018–2026 ($MILLION)
TABLE 10.HEMATOLOGICAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY PCR-BASED TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 11.HEMATOLOGICAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY NGS BASED TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 12.HEMATOLOGICAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY FLOW CYTOMETRY BASED TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 13.HEMATOLOGICAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY FISH BASED TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 14.HEMATOLOGICAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY CISH BASED TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 15.HEMATOLOGICAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY OTHERS BASED TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 16.ASIA PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET FOR BREAST CANCER , 2018–2026 ($MILLION)
TABLE 17.BREAST ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY PCR-BASED TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 18.BREAST ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY NGS BASED TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 19.BREAST ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY FLOW CYTOMETRY BASED TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 20.BREAST ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY FISH BASED TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 21.BREAST ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY CISH BASED TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 22.BREAST ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY OTHERS BASED TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 23.ASIA PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET FOR LUNG CANCER , 2018–2026 ($MILLION)
TABLE 24.LUNG ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY PCR-BASED TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 25.LUNG ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY NGS BASED TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 26.LUNG ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY FLOW CYTOMETRY BASED TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 27.LUNG ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY FISH BASED TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 28.LUNG ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY CISH BASED TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 29.LUNG ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY OTHERS BASED TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 30.ASIA PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET FOR OTHERS , BY COUNTRY , 2018–2026 ($MILLION)
TABLE 31.OTHERS ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY PCR-BASED TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 32.OTHERS ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY NGS BASED TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 33.OTHERS ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY FLOW CYTOMETRY BASED TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 34.OTHERS ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY FISH BASED TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 35.OTHERS ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY CISH BASED TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 36.OTHERS ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY OTHERS BASED TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 37.ASIA-PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY END USER 2018–2026 ($MILLION)
TABLE 38.ASIA PACIFIC ASIA-PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY , 2018–2026 ($MILLION)
TABLE 39.ASIA PACIFIC ASIA-PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES , BY COUNTRY , 2018–2026 ($MILLION)
TABLE 40.ASIA PACIFIC ASIA-PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET FOR OTHERS , BY COUNTRY , 2018–2026 ($MILLION)
TABLE 41.ASIA-PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 42.AUSTRALIA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 43.AUSTRALIA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2018–2026 ($MILLION)
TABLE 44.VIETNAM ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 45.VIETNAM ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2018–2026 ($MILLION)
TABLE 46.THAILAND ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 47.THAILAND ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2018–2026 ($MILLION)
TABLE 48.PHILLIPINES ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 49.PHILLIPINES ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2018–2026 ($MILLION)
TABLE 50.REST OF ASIA PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 51.REST OF ASIA-PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2018–2026 ($MILLION)
TABLE 52.ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 53.ABBOTT LABORATORIES: OPERATING SEGMENTS
TABLE 54.ABBOTT LABORATORIES: PRODUCT PORTFOLIO
TABLE 55.BIOMEREUX SA: COMPANY SNAPSHOT
TABLE 56.BIOMEREUX SA: PRODUCT PORTFOLIO
TABLE 57.BIOMEREUX SA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 58.QIAGEN N.V.: COMPANY SNAPSHOT
TABLE 59.QIAGEN N.V.: OPERATING SEGMENT
TABLE 60.QIAGEN N.V.: PRODUCT PORTFOLIO
TABLE 61.QIAGEN: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 62.F. HOFFMAN-LA ROCHE LTD: COMPANY SNAPSHOT
TABLE 63.F. HOFFMAN-LA ROCHE LTD: OPERATING SEGMENTS
TABLE 64.F. HOFFMAN-LA ROCHE LTD: PRODUCT PORTFOLIO
TABLE 65.F. HOFFMAN-LA ROCHE LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 66.SIEMENS HEALTHINEERS: COMPANY SNAPSHOT
TABLE 67.SIEMENS HEALTHINEERS: OPERATING SEGMENTS
TABLE 68.SIEMENS HEALTHINEERS: PRODUCT PORTFOLIO
TABLE 69.DANAHER CORPORATION: COMPANY SNAPSHOT
TABLE 70.DANAHER CORPORATION: OPERATING SEGMENTS
TABLE 71.DANAHER CORPORATION: PRODUCT PORTFOLIO
TABLE 72.DANAHER CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 73.DIASORIN SPA: COMPANY SNAPSHOT
TABLE 74.DIASORIN SPA: PRODUCT PORTFOLIO
TABLE 75.DIASORIN SPA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 76.ILLUMINA INC.: COMPANY SNAPSHOT
TABLE 77.ILLUMINA INC.: OPERATING SEGMENTS
TABLE 78.ILLUMINA INC.: PRODUCT PORTFOLIO
TABLE 79.ILLUMINA INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 80.AGILENT TECHNOLOGIES INC.: COMPANY SNAPSHOT
TABLE 81.AGILENT TECHNOLOGIES INC.: OPERATING SEGMENTS
TABLE 82.AGILENT TECHNOLOGIES INC: PRODUCT PORTFOLIO
TABLE 83.AGILENT TECHNOLOGIES INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 84.SYSMEX CORPORATION: COMPANY SNAPSHOT
TABLE 85.SYSMEX CORPORATION: OPERATING SEGMENTS
TABLE 86.SYSMEX CORPORATION: PRODUCT PORTFOLIO
TABLE 87.SYSMEX CORPORATION.: KEY STRATEGIC MOVES AND DEVELOPMENTS
Similar Reports
Medical implants are permanent devices such as pacemakers or temporary devices such as fracture plates which are removed once their function is completed. These implants are made up of bone, tissue, skin, ceramics, metals, plastics, and other natural materials...
- Publish Date: August 21, 2016
- $5370
Ostomy is a surgery wherein an artificial opening, known as stoma, is created from the colon in the human body to eliminate body wastes such as urine, mucus, and stools, which are collected in artificial bags called ostomy drainage bags. These plastic/rub...
- Publish Date: December 1, 2016
- $5370
Laparoscopy is a minimally invasive procedure used to examine organs inside the abdomen or pelvic cavities by inserting a laparoscope through a small incision in the abdomen. A laparoscope comprises a long, thin tube with high-intensity light, and high-re...
- Publish Date: April 24, 2017
- $5370
